CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 36,000 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 36,000 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $21.00, for a total transaction of $756,000.00. Following the sale, the chief financial officer owned 118,842 shares in the company, valued at $2,495,682. The trade was a 23.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

CeriBell Trading Up 0.4%

Shares of CBLL stock opened at $21.39 on Tuesday. The stock has a market capitalization of $793.57 million, a price-to-earnings ratio of -14.17 and a beta of 1.30. The company’s fifty day simple moving average is $16.31 and its two-hundred day simple moving average is $14.80. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $26.83. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The firm had revenue of $22.59 million during the quarter, compared to analyst estimates of $21.78 million. As a group, analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. Raymond James Financial started coverage on shares of CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target for the company. Cowen reiterated a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. JPMorgan Chase & Co. reduced their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Finally, TD Cowen decreased their target price on CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell currently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

Institutional Trading of CeriBell

A number of hedge funds have recently made changes to their positions in the stock. Sherbrooke Park Advisers LLC purchased a new position in CeriBell in the third quarter worth $135,000. Millennium Management LLC lifted its stake in CeriBell by 41.8% during the third quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock worth $7,657,000 after purchasing an additional 196,299 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of CeriBell by 87.1% in the 3rd quarter. Bank of America Corp DE now owns 135,783 shares of the company’s stock worth $1,560,000 after purchasing an additional 63,215 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of CeriBell during the 3rd quarter valued at about $33,000. Finally, Two Sigma Investments LP raised its holdings in shares of CeriBell by 81.0% during the 3rd quarter. Two Sigma Investments LP now owns 297,963 shares of the company’s stock valued at $3,424,000 after buying an additional 133,324 shares in the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.